Coating nanoparticles with cell membranes for targeted drug delivery

References

• Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 2014;9:223–43
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014;13:655–72
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11:S81–S91
   PubMed Web of Science ®Google Scholar
• Chertok B, Webber MJ, Succi MD, Langer R. Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies. Mol Pharm 2013;10:3531–43
   PubMed Web of Science ®Google Scholar
• Langer R. New methods of drug delivery. Science 1990;249:1527–33
   PubMed Web of Science ®Google Scholar
• Langer R. Drug delivery and targeting. Nature 1998;392:5–10
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16–20
   PubMed Web of Science ®Google Scholar
• Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010;10:3223–30
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a psma-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:article 128ra39
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006;58:1456–9
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Alexis F, Rhee J-W, Richie JP, et al. New frontiers in nanotechnology for cancer treatment. Urol Oncol Semin Ori 2008;26:74–85
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces 2014;6:21859–73
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283–318
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185–98
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505–15
   PubMed Web of Science ®Google Scholar
• Barua S, Mitragotri S. Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. ACS Nano 2013;7:9558–70
   PubMed Web of Science ®Google Scholar
• Kolhar P, Anselmo AC, Gupta V, et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci USA 2013;110:10753–8
   PubMed Web of Science ®Google Scholar
• Barua S, Yoo J-W, Kolhar P, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA 2013;110:3270–5
   PubMed Web of Science ®Google Scholar
• Lee H, Lytton-Jean AKR, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 2012;7:389–93
   PubMed Web of Science ®Google Scholar
• Kamaly N, Fredman G, Subramanian M, et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci USA 2013;110:6506–11
   PubMed Web of Science ®Google Scholar
• Leserman LD, Barbet J, Kourilsky F, Weinstein JN. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein-a. Nature 1980;288:602–4
   PubMed Web of Science ®Google Scholar
• Heath TD, Fraley RT, Papahadjopoulos D. Antibody targeting of liposomes – cell specificity obtained by conjugation of f(ab')2 to vesicle surface. Science 1980;210:539–41
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng JJ, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315–20
   PubMed Web of Science ®Google Scholar
• Valencia PM, Hanewich-Hollatz MH, Gao W, et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011;32:6226–33
   PubMed Web of Science ®Google Scholar
• Farokhzad OC. Using ligands to target cancer cells. Clin Adv Hematol Oncol 2012;10:543–4
   PubMedGoogle Scholar
• Gao W, Chan JM, Farokhzad OC. Ph-responsive nanoparticles for drug delivery. Mol Pharm 2010;7:1913–20
   PubMed Web of Science ®Google Scholar
• Radovic-Moreno AF, Lu TK, Puscasu VA, et al. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 2012;6:4279–87
   PubMed Web of Science ®Google Scholar
• Choi WI, Kamaly N, Riol-Blanco L, et al. A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins. Nano Lett 2014;14:6449–55
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761–9
   PubMed Web of Science ®Google Scholar
• Veiseh O, Tang BC, Whitehead KA, et al. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov 2015;14:45–57
   PubMed Web of Science ®Google Scholar
• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012;12:39–50
   Web of Science ®Google Scholar
• Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011;44:1123–34
   PubMed Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971–3010
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, et al. Phase i and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in peg immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004;15:517–25
   PubMed Web of Science ®Google Scholar
• Phan A, Takimoto C, Adinin R, et al. Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. Mol Cancer Ther 2007;6:3563S
   Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067–70
   PubMed Web of Science ®Google Scholar
• Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659–68
   PubMed Web of Science ®Google Scholar
• Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 2004;428:487–92
   PubMed Web of Science ®Google Scholar
• Wegst UGK, Bai H, Saiz E, et al. Bioinspired structural materials. Nat Mater 2015;14:23–36
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater 2013;12:978–90
   PubMed Web of Science ®Google Scholar
• Najer A, Wu D, Bieri A, et al. Nanomimics of host cell membranes block invasion and expose invasive malaria parasites. ACS Nano 2014;8:12560–71
   PubMed Web of Science ®Google Scholar
• Balmert SC, Little SR. Biomimetic delivery with micro- and nanoparticles. Adv Mater 2012;24:3757–78
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108:10980–5
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Copp J, et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol 2013;8:336–40
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol 2013;8:933–8
   PubMed Web of Science ®Google Scholar
• Gao W, Zhang L. Engineering red blood cell membrane-coated nanoparticles for broad biomedical applications. AIChE J 2015;61:738–46
   Web of Science ®Google Scholar
• Gao W, Hu C-MJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. J Mater Chem B 2013;1:6569–85
   Web of Science ®Google Scholar
• Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Luk BT, Zhang L. Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale 2014;6:65–75
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Healthc Mater 2012;1:537–47
   PubMed Web of Science ®Google Scholar
• Wu Z, Li T, Li J, et al. Turning erythrocytes into functional micromotors. ACS Nano 2014;8:12041–8
   PubMed Web of Science ®Google Scholar
• Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403–27
   PubMed Web of Science ®Google Scholar
• Luk BT, Hu C-MJ, Fang RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014;6:2730–7
   PubMed Web of Science ®Google Scholar
• Rodriguez PL, Harada T, Christian DA, et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013;339:971–5
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Luk BT, et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 2013;5:2664–8
   PubMed Web of Science ®Google Scholar
• Gao W, Langer R, Farokhzad OC. Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed 2010;49:6567–71
   PubMed Web of Science ®Google Scholar
• Gao W, Hu C-MJ, Fang RH, et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater 2013;25:3549–53
   PubMed Web of Science ®Google Scholar
• Piao J-G, Wang L, Gao F, et al. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 2014;8:10414–25
   PubMed Web of Science ®Google Scholar
• Li L-L, Xu J-H, Qi G-B, et al. Core-shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery. ACS Nano 2014;8:4975–83
   PubMed Web of Science ®Google Scholar
• Copp JA, Fang RH, Luk BT, et al. Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci USA 2014;111:13481–6
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008;105:2586–91
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 2013;5:article 213ra167
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu C-MJ, Chen KNH, et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 2013;5:8884–8
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu C-MJ, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 2014;14:2181–8
   PubMed Web of Science ®Google Scholar
• Khaldoyanidi SK, Glinsky VV, Sikora L, et al. Mda-mb-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by thomsen-friedenreich antigen-galectin-3 interactions. J Biol Chem 2003;278:4127–34
   PubMed Web of Science ®Google Scholar
• Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 2003;63:3805–11
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells. J Exp Med 2003;198:569–80
   PubMed Web of Science ®Google Scholar
• Gao W, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett 2015;15:1403–9
   PubMed Web of Science ®Google Scholar
• Jewell CM, Lopez SCB, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci USA 2011;108:15745–50
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25:1159–64
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014;507:519–22
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011;10:243–51
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Li AV, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand t-fh cells and promote germinal center induction. Proc Natl Acad Sci USA 2012;109:1080–5
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L. Nanotoxoid vaccines. Nano Today 2014;9:401–4
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Wardenburg JB, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of usa300 skin infection in a mouse model. J Infect Dis 2010;202:1050–8
   PubMed Web of Science ®Google Scholar
• Kernodle DS. Expectations regarding vaccines and immune therapies directed against staphylococcus aureus alpha-hemolysin. J Infect Dis 2011;203:1692–3
   PubMed Web of Science ®Google Scholar
• Fan Z, Zhou H, Li PY, et al. Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J Mater Chem B 2014;2:8231–8
   PubMed Web of Science ®Google Scholar
• Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013;8:61–8
   PubMed Web of Science ®Google Scholar
• Johannes L, Roemer W. Shiga toxins – from cell biology to biomedical applications. Nat Rev Microbiol 2010;8:105–16
   PubMed Web of Science ®Google Scholar
• Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 2014;12:535–49
   PubMed Web of Science ®Google Scholar